Now Enrolling in Breast Cancer

Phase II • NCT05852691 • RO7247669

A randomized, multicenter, double-blind study of RO7247669 (tobemstomig, an anti-PD1-LAG3 bispecific antibody) plus nab-paclitaxel versus pembrolizumab plus nab-paclitaxel in patients with previously untreated, PD-L1-positive, locally advanced unresectable or metastatic triple-negative breast cancer (TNBC)

SCHEMA

Key Eligibility Criteria
- Histologically confirmed locally advanced unresectable or metastatic TNBC
- Measurable disease per RECIST v1.1
  - If metastatic disease, measurable disease outside of the bone
- No prior treatment in the advanced/metastatic setting
- PD-L1-positive
- ECOG PS 0 or 1

Primary Outcome Measure:
- PFS

Secondary Outcome Measures:
- ORR
- DoR
- OS
- PFS and OS rate at 12 months
- PK/PD analysis
- Incidence of ADAs

LOCATIONS
Argentina
Australia
Brazil
Czech Republic
Denmark
Germany
Ghana
Hungary
Israel
Italy
Ivory Coast
Kenya
Mexico
Netherlands
Nigeria
Peru
Poland
South Africa
South Korea
Spain
Switzerland
Taiwan
Turkey
Uganda
USA

STUDY ENDPOINTS

Visit: ClinicalTrials.gov
Email: global.rochegenentechtrials@roche.com

ClinicalTrials.gov Identifier: NCT05852691

Information is consistent with ClinicalTrials.gov as of September 18, 2023. Products under investigation have not been approved for use outside of the clinical trial setting. This information is presented only for the purposes of providing an overview of clinical trials and should not be construed as a recommendation for use of any product for unapproved purposes.